Pearl Therapeutics Gets $69M

Xconomy San Francisco — 

Pearl Therapeutics, a Redwood City, CA-based developer of treatments for chronic respiratory diseases, said today it has raised $69 million in a Series C venture financing. The investment was led by Vatera Healthcare Partners, and included Clarus Ventures, New Leaf Ventures and 5AM Ventures. The company plans to use the cash to complete a mid-stage clinical trial of its lead drug candidate, PT003, for chronic obstructive pulmonary disease.